GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (LTS:0A3M) » Definitions » Preferred Dividends

BioNTech SE (LTS:0A3M) Preferred Dividends : $0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. BioNTech SE's preferred dividends for the three months ended in Sep. 2024 was $0 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Sep. 2024 was $0 Mil.


BioNTech SE Preferred Dividends Historical Data

The historical data trend for BioNTech SE's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Preferred Dividends Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Preferred Dividends
Get a 7-Day Free Trial - - - - -

BioNTech SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioNTech SE Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.


BioNTech SE  (LTS:0A3M) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioNTech SE Business Description

Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

BioNTech SE Headlines

No Headlines